Recommended Topic Related To:


"The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

ALL is the most common type of pediatric "...



Arzerra Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Arzerra (ofatumumab) Injection is a monoclonal antibody used in to treat chronic lymphocytic leukemia. It is usually given after other medications have been tried without successful treatment of symptoms. Common side effects include nausea, vomiting, diarrhea, tiredness, swelling of hands/ankles/feet, or trouble sleeping.

The recommended dosage and schedule of Arzerra is 12 doses administered as follows: 300 mg initial dose (Dose 1), followed 1 week later by 2,000 mg weekly for 7 doses (Doses 2 through 8), followed 4 weeks later by 2,000 mg every 4 weeks for 4 doses (Doses 9 through 12). Arzerra may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Arzerra should be used only if prescribed. It is unknown if this drug passes into breast milk and may have undesirable effects on a nursing infant. Consult your doctor before breastfeeding.

Our Arzerra (ofatumumab) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Patient Information in Detail?

Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.

Arzerra in Detail - Patient Information: Side Effects

Some people receiving a ofatumumab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, nauseated, light-headed, confused, itchy, tingly, or have chest pain, jaw or arm pain, back pain, stomach pain, wheezing, chest tightness, or trouble breathing. These reactions can occur during the injection or within 24 hours afterward..

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have any of these serious side effects:

  • change in your mental state, problems with speech or walking, decreased vision (these symptoms may start gradually and get worse quickly);
  • nausea, stomach pain, loss of appetite, itching, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
  • fever, chills, body aches, flu symptoms, mouth and throat ulcers, rapid heart rate, rapid and shallow breathing, fainting;
  • easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin;
  • cough with yellow or green mucus, stabbing chest pain, feeling short of breath;
  • confusion, weakness on one side of the body, loss of balance or coordination; or
  • severe constipation.

Less serious side effects may include:

  • mild nausea, diarrhea;
  • swelling in your hands or feet.
  • cold symptoms such as stuffy nose, sneezing, sore throat;
  • tired feeling; or
  • mild skin rash.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Arzerra (Ofatumumab Injection) »

What is Patient Information Overview?

A concise overview of the drug for the patient or caregiver from First DataBank.

Arzerra Overview - Patient Information: Side Effects

SIDE EFFECTS: See also How to Use section.

Nausea, vomiting, diarrhea, tiredness, swelling of hands/ankles/feet, or trouble sleeping may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

Many people using this medication have serious side effects. However, your doctor has prescribed this drug because he or she has judged that the benefit to you is greater than the risk of side effects. Careful monitoring by your doctor may decrease your risk.

This medication decreases bone marrow function, an effect that may lead to a low number of blood cells such as red cells, white cells, and platelets. This effect can cause anemia, decrease your body's ability to fight an infection, or cause easy bruising/bleeding. Your doctor will order blood tests to check for this side effect. It is important to keep all medical/lab test appointments. Tell your doctor immediately if you develop any of the following symptoms: easy bruising/bleeding, pale skin, unusual tiredness, signs of infection (such as fever, chills, cough, persistent sore throat).

Ofatumumab may rarely cause serious (possibly fatal) liver disease in people exposed to hepatitis B virus. Your doctor may order blood tests and watch for symptoms during treatment and for 6 to 12 months after your last treatment. Seek immediate medical attention if you have any symptoms of liver damage, including: persistent nausea/vomiting, stomach/abdominal pain, dark urine, yellowing eyes/skin.

Ofatumumab increases your risk of getting a rare but very serious (sometimes fatal) brain infection (progressive multifocal leukoencephalopathy-PML). Tell your doctor immediately if any of these rare but very serious side effects occur: loss of balance/dizziness, confusion, difficulty walking or talking, seizure, vision changes.

A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the entire patient information overview for Arzerra (Ofatumumab Injection)»

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Arzerra FDA Prescribing Information: Side Effects
(Adverse Reactions)


The following serious adverse reactions are discussed in greater detail in other sections of the labeling:

The most common adverse reactions ( ≥ 10%) in Study 1 were neutropenia, pneumonia, pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash, nausea, bronchitis, and upper respiratory tract infections.

The most common serious adverse reactions in Study 1 were infections (including pneumonia and sepsis), neutropenia, and pyrexia. Infections were the most common adverse reactions leading to drug discontinuation in Study 1.

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of monotherapy with ARZERRA was evaluated in 181 patients with relapsed or refractory CLL in 2 open-label, non-randomized, single-arm studies. In these studies, ARZERRA was administered at 2,000 mg beginning with the second dose for 11 doses (Study 1 [n = 154]) or 3 doses (Study 2 [n = 27]).

The data described in Table 2 and other sections below are derived from 154 patients in Study 1. All patients received 2,000 mg weekly from the second dose onward. Ninety percent of patients received at least 8 infusions of ARZERRA and 55% received all 12 infusions. The median age was 63 years (range: 41 to 86 years), 72% were male, and 97% were White.

Table 2: Incidence of All Adverse Reactions Occurring in ≥ 5% of Patients in Study 1 and in the Fludarabine-and Alemtuzumab-Refractory Subset of Study 1 (MedDRA 9.0)

  Total Population
(n =154)
Fludarabine- and Alemtuzumab-Refractory
(n =59)
All Grades Grade ≥ 3 All Grades Grade ≥ 3
Body System/Adverse Event % % % %
Infections and infestations
  Pneumoniaa 23 14 25 15
  Upper respiratory tract infection 11 0 3 0
  Bronchitis 11 < 1 19 2
  Sepsisb 8 8 10 10
  Nasopharyngitis 8 0 8 0
  Herpes zoster 6 1 7 2
  Sinusitis 5 2 3 2
Blood and lymphatic system disorders
  Anemia 16 5 17 8
Psychiatric disorders
  Insomnia 7 0 10 0
Nervous system disorders
  Headache 6 0 7 0
Cardiovascular disorders
  Hypertension 5 0 8 0
  Hypotension 5 0 3 0
  Tachycardia 5 < 1 7 2
Respiratory, thoracic, and mediastinal disorders
  Cough 19 0 19 0
  Dyspnea 14 2 19 5
Gastrointestinal disorders
  Diarrhea 18 0 19 0
  Nausea 11 0 12 0
Skin and subcutaneous tissue disorders
  Rashc 14 < 1 17 2
  Urticaria 8 0 5 0
  Hyperhidrosis 5 0 5 0
Musculoskeletal and connective tissue disorders
  Back pain 8 1 12 2
  Muscle spasms 5 0 3 0
General disorders and administration site conditions
  Pyrexia 20 3 25 5
  Fatigue 15 0 15 0
  Edema peripheral 9 < 1 8 2
  Chills 8 0 10 0
aPneumonia includes pneumonia, lung infection, lobar pneumonia, and bronchopneumonia.
bSepsis includes sepsis, neutropenic sepsis, septic shock.
c Rash includes rash, rash macular, and rash vesicular.

Infusion Reactions

Infusion reactions occurred in 44% of patients on the day of the first infusion (300 mg), 29% on the day of the second infusion (2,000 mg), and less frequently during subsequent infusions.


A total of 108 patients (70%) experienced bacterial, viral, or fungal infections. A total of 45 patients (29%) experienced ≥ Grade 3 infections, of which 19 (12%) were fatal. The proportion of fatal infections in the fludarabine-and alemtuzumab-refractory group was 17%.


Of 108 patients with normal neutrophil counts at baseline, 45 (42%) developed ≥ Grade 3 neutropenia. Nineteen (18%) developed Grade 4 neutropenia. Some patients experienced new onset Grade 4 neutropenia > 2 weeks in duration.


There is a potential for immunogenicity with therapeutic proteins such as ofatumumab. Serum samples from patients with CLL in Study 1 were tested by enzyme-linked immunosorbent assay (ELISA) for anti-ofatumumab antibodies during and after the 24-week treatment period. Results were negative in 46 patients after the 8th infusion and in 33 patients after the 12th infusion.

Immunogenicity assay results are highly dependent on several factors including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies to ARZERRA with the incidence of antibodies to other products may be misleading.

Read the entire FDA prescribing information for Arzerra (Ofatumumab Injection) »


Arzerra - User Reviews

Arzerra User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Arzerra sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.

Health Resources
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations